460 related articles for article (PubMed ID: 22200790)
1. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).
Hafsi S; Pezzino FM; Candido S; Ligresti G; Spandidos DA; Soua Z; McCubrey JA; Travali S; Libra M
Int J Oncol; 2012 Mar; 40(3):639-44. PubMed ID: 22200790
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
3. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival.
Barata JT
Adv Enzyme Regul; 2011; 51(1):37-49. PubMed ID: 21035501
[TBL] [Abstract][Full Text] [Related]
4. PTEN, more than the AKT pathway.
Blanco-Aparicio C; Renner O; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
[TBL] [Abstract][Full Text] [Related]
5. [PI3K inhibitor].
Yano S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Ohtsubo K; Yasumoto K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):23-6. PubMed ID: 21368457
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN.
Kim JH; Kang TH; Noh KH; Kim SH; Lee YH; Kim KW; Bae HC; Ahn YH; Choi EY; Kim JS; Lee KM; Kim TW
Immunol Lett; 2010 Nov; 134(1):47-54. PubMed ID: 20727912
[TBL] [Abstract][Full Text] [Related]
7. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
Carnero A; Blanco-Aparicio C; Renner O; Link W; Leal JF
Curr Cancer Drug Targets; 2008 May; 8(3):187-98. PubMed ID: 18473732
[TBL] [Abstract][Full Text] [Related]
8. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Meng Q; Xia C; Fang J; Rojanasakul Y; Jiang BH
Cell Signal; 2006 Dec; 18(12):2262-71. PubMed ID: 16839745
[TBL] [Abstract][Full Text] [Related]
9. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
Nozhat Z; Hedayati M
Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
[TBL] [Abstract][Full Text] [Related]
10. PI3K/PTEN signaling in tumorigenesis and angiogenesis.
Jiang BH; Liu LZ
Biochim Biophys Acta; 2008 Jan; 1784(1):150-8. PubMed ID: 17964232
[TBL] [Abstract][Full Text] [Related]
11. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
[TBL] [Abstract][Full Text] [Related]
12. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
[TBL] [Abstract][Full Text] [Related]
13. PTEN and PI3K/AKT in non-small-cell lung cancer.
Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Faus-Dáder MJ; Calleja-Hernández MÁ
Pharmacogenomics; 2015 Nov; 16(16):1843-62. PubMed ID: 26555006
[TBL] [Abstract][Full Text] [Related]
14. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
[TBL] [Abstract][Full Text] [Related]
15. Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.
Park YH; Jung HH; Ahn JS; Im YH
Biochem Biophys Res Commun; 2013 Sep; 439(2):275-9. PubMed ID: 23973711
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic PI3K and its role in cancer.
Samuels Y; Ericson K
Curr Opin Oncol; 2006 Jan; 18(1):77-82. PubMed ID: 16357568
[TBL] [Abstract][Full Text] [Related]
17. PI(3)king apart PTEN's role in cancer.
Zhang S; Yu D
Clin Cancer Res; 2010 Sep; 16(17):4325-30. PubMed ID: 20622047
[TBL] [Abstract][Full Text] [Related]
18. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
Dan S; Okamura M; Seki M; Yamazaki K; Sugita H; Okui M; Mukai Y; Nishimura H; Asaka R; Nomura K; Ishikawa Y; Yamori T
Cancer Res; 2010 Jun; 70(12):4982-94. PubMed ID: 20530683
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs as important players in regulating cancer through PTEN/PI3K/AKT signalling pathways.
Selvakumar SC; Preethi KA; Sekar D
Biochim Biophys Acta Rev Cancer; 2023 May; 1878(3):188904. PubMed ID: 37142060
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT signaling pathway and cancer: an updated review.
Martini M; De Santis MC; Braccini L; Gulluni F; Hirsch E
Ann Med; 2014 Sep; 46(6):372-83. PubMed ID: 24897931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]